CN105796662A - Psyllium seed husk powder and inulin composition - Google Patents
Psyllium seed husk powder and inulin composition Download PDFInfo
- Publication number
- CN105796662A CN105796662A CN201610200045.2A CN201610200045A CN105796662A CN 105796662 A CN105796662 A CN 105796662A CN 201610200045 A CN201610200045 A CN 201610200045A CN 105796662 A CN105796662 A CN 105796662A
- Authority
- CN
- China
- Prior art keywords
- inulin
- group
- circle bud
- preparation
- bud cillium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 title claims abstract description 81
- 229920001202 Inulin Polymers 0.000 title claims abstract description 78
- 229940029339 inulin Drugs 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 77
- 239000000843 powder Substances 0.000 title claims abstract description 17
- 239000010903 husk Substances 0.000 title abstract description 4
- 235000010451 Plantago psyllium Nutrition 0.000 title abstract 3
- 244000090599 Plantago psyllium Species 0.000 title abstract 3
- 230000000968 intestinal effect Effects 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 238000010521 absorption reaction Methods 0.000 claims abstract description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 9
- 239000011707 mineral Substances 0.000 claims abstract description 9
- 238000009826 distribution Methods 0.000 claims abstract description 5
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims description 25
- 206010010774 Constipation Diseases 0.000 claims description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 239000003826 tablet Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 14
- -1 electuary Substances 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 9
- 241000207199 Citrus Species 0.000 claims description 8
- 235000010489 acacia gum Nutrition 0.000 claims description 8
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 8
- 235000020971 citrus fruits Nutrition 0.000 claims description 8
- 239000012467 final product Substances 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 6
- 239000007888 film coating Substances 0.000 claims description 6
- 238000009501 film coating Methods 0.000 claims description 6
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000007943 implant Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 239000007941 film coated tablet Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 244000241257 Cucumis melo Species 0.000 claims description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 244000290333 Vanilla fragrans Species 0.000 claims description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 claims description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229960004667 ethyl cellulose Drugs 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 230000007413 intestinal health Effects 0.000 abstract 1
- 230000002040 relaxant effect Effects 0.000 abstract 1
- 230000006870 function Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 14
- 229960005069 calcium Drugs 0.000 description 14
- 239000011575 calcium Substances 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- 230000013872 defecation Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 238000003304 gavage Methods 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000000582 semen Anatomy 0.000 description 9
- 229960004192 diphenoxylate Drugs 0.000 description 8
- 239000000976 ink Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002366 mineral element Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 229940042228 calcium gluconate oral solution Drugs 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 108010011619 6-Phytase Proteins 0.000 description 2
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229940003871 calcium ion Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000209510 Liliopsida Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 241001532014 Xanthorrhoea Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940042003 metamucil Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of medicinal biotechnology, and relates to a composition containing psyllium seed husk powder and inulin and a preparation method of the composition.The composition is prepared from psyllium seed husk powder and inulin at the weight ratio of (48-78):(10-40).The composition has the effects of relaxing bowels, improving distribution of human intestinal floras, regulating intestinal health and balancing mineral matter absorption.
Description
Technical field
The invention belongs to field of pharmaceutical biology, relate to a kind of containing circle bud Cillium and inulin composition with functions and preparation method thereof, said composition can play good loosening bowel to relieve constipation, improves the distribution of human body intestinal canal flora, regulating intestinal canal is healthy, the effect of balance mineral absorption.
Background technology
Raising along with people's living standard, the change of dietary habit, people are more in diet takes in the food that polished rice flour is made, add due to higher fatty acid, high sugar, the energy-dense foods such as high protein are taken in too much, cellulose in food is not enough, intestinal can not be formed a certain amount of stimulation, enterokinesia is slow, food debris can not be pushed to rectum in time, at enteral extended residence time, these can not discharge internal residue in time by corruption, fermentation forms stool, cause constipation, also results in people's hyperglycemia, obesity, the generally generation of the modern diseasies such as the multiple cardiovascular and cerebrovascular disease of hyperlipemia and initiation thereof.Therefore, develop product low in calories, high dietary fiber content, improve the balanced diet of people, just become a trend of social life development.
The medicine treating constipation in the market inherently can cause iatrogenic constipation, such as phenolphthalein, liquid paraffin, glycerol, magnesium sulfate etc., the irritability of intestinal wall nerve receptor cell can be reduced after prolonged application, make enterokinesia and defecation reflex paralysis, form obstinate " cathartic is additive " constipation.And health food containing the relieving constipation compositions such as Folium Sennae, Radix Et Rhizoma Rhei, Aloe on market, the nerve in colon wall can be destroyed after long-term taking, make intestinal wall sensation paralysis, lose the perception of feces in enteric cavity, therefore intestinal loses normal physiological function, causes that constipation occurs.
Circle bud Semen Plantaginis is also known as ocean Herba Plantaginis, it it is a kind of medical herbs of Ginuceae section, originate in India, Iran, in Mediterranean Region country, also cultivation is had in states such as France, Spain, circle bud psyllium husk, rich in colloid (Mucilage, Metamucil), is made up of arabinose, xylose, half latex aldehydic acid, partial desiccation fatty oil and a small amount of aucubin (Aucubine).In circle bud Semen Plantaginis shell, fiber content accounts for 80%, and other nutritional labelings mainly include glycoside, protein, polysaccharide, vitamin B1 and choline.Circle bud Semen Plantaginis can form the gel group of 8～14 times of volumes after entering intestinal water suction, can maintain moisture and the pliability of feces, and gel group also can stimulate intestinal wall to produce reflex contraction effect, and promote that intestinal empties normally.
Patent CN201410187616 " a kind of Testa Tritici puffed food " adopts Testa Tritici and Cillium as primary raw material, carries out extruding puffing in the magazine sending into twin-screw extruder that stirs then through adding water and obtain Testa Tritici puffed food.This based food is a kind of foods with high dietary fiber, but wherein Testa Tritici accounts for main component, after the fiber of high-load makes this product edible, some mineral absorption internal is affected, and production technology is complex, finally giving product is puffed food, and this can make a lot of consumer focusing on health hang back.Patent KR101487769 has invented and a kind of has enhanced metabolism, increases intestinal peristalsis promoting, the anti-food treated constipation, this food principal agent composition is circle bud Semen Plantaginis shell, aspergillus oryzae and Aloe extract, by adding aspergillus oryzae, strengthen food Fermentation in human body, enhance metabolism, and utilize circle bud Semen Plantaginis shell to improve the degree of lubrication of feces and intestinal, prevent treating constipation；Patent KR20140028749 have also been invented the health food of a kind of constipation of losing weight and improve, and main composition is circle bud Semen Plantaginis shell and blite, and blite is mainly the effect of clearing away heat-damp and promoting diuresis, and this product is mainly for constipation patient.
But the side chain such as the hydroxyl or carboxyl of institute can be combined with some mineral element and affect mineral metabolism balance in human body intestinal canal in circle bud Semen Plantaginis shell.
Inulin (Inulin) is deposit property polysaccharide in plant, is mainly derived from plant, it has been found that have kind more than 36000, the Liliaceae in 11 sections and monocotyledon, the grass tree section such as including the Compositae in dicotyledon, campanulaceae, Gentianaceae.It is a kind of natural low-caloricity carbohydrate, is also a kind of water soluble dietary fiber, containing the mixture of multiple different polymerization degree levan, or a kind of carbohydrate being not result in blood glucose and raising.Inulin can remarkably promote the breeding of the probiotics such as bacillus bifidus and lactobacillus in large intestine, suppresses the growth of the harmful bacterias such as clostridium, bacteroid and escherichia coli simultaneously, and this shows, inulin is only capable of by probiotics institute digestibility and utilization in large intestine.Adding inulin can make food convert to the direction of low sugar, low fat, high dietary-fiber, and the original local flavor that simultaneously can as far as possible keep again food is unaffected, and this makes inulin easily be esthetically acceptable to the consumers.And inulin is also of great advantage to health.Inulin contributes to controlling blood sugar level, reduces the amount of cholesterol.The metabolite of inulin can promote the synthesis of vitamin B group and folic acid, improves the metabolism of body, improves immunity and premunition.
Research shows, inulin can promote mineral element such as Ca2+、Mg2+、Zn2+、Cu2+And Fe2+Deng absorption.The volatile fatty acid that inulin fermentation generates makes H in large intestine+Lowering of concentration, promotes the dissolving of various mineral in daily ration, it addition, the H produced+Also with metal ion exchanged, can promote that it absorbs；Inulin ferments in mice large intestine, promotes some microorganism secretion phytases, and phytase can make the Metal ion release with phytic acid chelating out, promotes that it absorbs；Some organic acid that fermentation generates with metal ion-chelant, can promote Metal Ions Absorption.
This function of inulin compensate for the deficiency of circle bud Semen Plantaginis shell function just.
Circle bud Cillium and inulin composition with functions provided by the invention, works in coordination with between the two mutually, play good loosening bowel to relieve constipation, improve the distribution of human body intestinal canal flora, regulating intestinal canal healthy, the effect of the absorption of balance mineral.It addition, present invention provides the method that said composition prepares into solid granules, capsule, tablet.
Summary of the invention
It is an object of the invention to provide a kind of loosening bowel to relieve constipation, improve the distribution of human body intestinal canal flora, regulating intestinal canal healthy, the compositions of balance mineral absorption.
Compositions of the present invention, the active component of said composition by justify bud Cillium and inulin form, the weight proportion of the two is: circle bud Cillium 53～73 weight portion；Inulin 5～25 weight portion.
Preferably, compositions of the present invention, it is made up of circle bud Cillium and two kinds of raw materials of inulin, the weight proportion of the two is: 68:10.
In compositions of the present invention, possibly together with pharmaceutically acceptable carrier.
The compositions of the present invention can be any edible dosage form, these dosage forms include: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, suspensoid, powder, preferably, tablet, electuary, capsule.
Wherein, electuary of the present invention, the one-tenth that following unit is weight portion it is grouped into:
Wherein, described sweeting agent is selected from: one or more in white sugar, saccharin sodium, aspartame, acesulfame potassium, stevioside, xylitol.
Wherein, described edible essence is selected from: one or more in Hami melon essence, vanilla, apple essence, Fructus Citri tangerinae essence, flavoring pineapple essence, fragrant citrus essence.
Capsule of the present invention, is grouped into by the one-tenth that following unit is weight portion:
Circle bud Cillium 53～73 weight portion
Inulin 5～25 weight portion
Lubricant 2～8 weight portion.
Wherein, described lubricant is one or more in magnesium stearate, Pulvis Talci, polyethylene glycols, differential silica gel.
Tablet of the present invention, is grouped into by the one-tenth that following unit is weight portion:
Wherein, described binding agent is one or more in water, ethanol, starch slurry, sodium carboxymethyl cellulose, hypromellose, low-substituted hydroxypropyl cellulose, methylcellulose and ethyl cellulose, cross-linking sodium carboxymethyl cellulose；
Wherein, described disintegrating agent is one or more in dried starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose；
Wherein, described lubricant is one or more in magnesium stearate, Pulvis Talci, polyethylene glycols, differential silica gel；
Wherein, described tablet is possibly together with the stomach dissolution type film coating powder of 3～8 weight portions.
Further object is that the preparation method that pharmaceutical composition is provided.
Preparation method of the present invention, mixes raw material and adjuvant according to conventional method on pharmaceutics, prepares into corresponding dosage form.
The preparation method of electuary of the present invention, comprises the following steps:
1) weigh circle bud Cillium, inulin, white sugar by formula ratio, cross 60 mesh sieves, standby；By formula ratio arabic gum, edible essence, standby；
2) by the arabic gum in step 1, edible essence is sufficiently mixed stirring according to equal increments method, obtains adjuvant mixture, standby；
3) by the circle bud Cillium in step 1, inulin, white sugar is sufficiently mixed with the adjuvant mixture of acquisition in step 2, obtains powder mixture, to obtain final product.
The preparation method of capsule of the present invention, comprises the following steps:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin is uniform with the mix lubricant of formula ratio；
3) according to implant weight needed for every capsules by 2) mixture is filled into capsulae vacuus.
The preparation method of tablet of the present invention, comprises the following steps:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin and the binding agent of formula ratio, disintegrating agent, mix lubricant are uniform；
3) sheet of 0.5～1.2g weight it is pressed into；
4) stomach dissolution type film coating powder is dissolved in ethanol so that it is dispersed；
5) sheet weighed up is put in coating pan, by 4) in solution be uniformly sprayed on sheet, to obtain final product.
Circle bud Cillium of the present invention broadly falls into existing product with inulin, can commercially buy.
Detailed description of the invention
Below in conjunction with the embodiment of the present invention; technical scheme in example of the present invention is clearly and completely described; described embodiment is only a part of embodiment in the present invention; rather than whole embodiments; based on the embodiment in the present invention; the every other embodiment that those of ordinary skill in the art obtain under not making creative work premise, broadly falls into the scope of protection of the invention.
Embodiment 1: prepared by the solid granules of circle bud Cillium and inulin composition with functions
Formula forms:
Preparation method:
1) formula ratio weighs circle bud Cillium, inulin, white sugar, crosses 60 mesh sieves, standby；By formula ratio arabic gum, fragrant citrus essence, standby；
2) by load weighted arabic gum, fragrant citrus essence is sufficiently mixed stirring according to equal increments method, obtains adjuvant mixture, standby；
3) by step 1) in circle bud Cillium, inulin, white sugar and step 2) in the adjuvant mixture that obtains be sufficiently mixed, obtain powder mixture, to obtain final product.
Embodiment 2: circle bud Cillium is prepared with inulin composition with functions solid granules
Formula forms:
Preparation method:
1) weigh circle bud Cillium, inulin, white sugar by formula ratio, cross 60 mesh sieves, standby；By formula ratio arabic gum, fragrant citrus essence, standby；
2) by load weighted arabic gum, fragrant citrus essence is sufficiently mixed stirring according to equal increments method, obtains adjuvant mixture, standby；
3) by step 1) in circle bud Cillium, inulin, white sugar and step 2) in the adjuvant mixture that obtains be sufficiently mixed, obtain powder mixture, be circle bud Cillium and inulin composition with functions.
Embodiment 3: circle bud Cillium is prepared with inulin composition with functions capsule
Formula forms:
Circle bud Cillium 680g
Inulin 100g
Pulvis Talci 4g
Preparation method:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin is mixed homogeneously with the Pulvis Talci of formula ratio；
3) according to implant weight needed for every capsules by step 2) mixture is filled into capsulae vacuus, makes 2000 capsules.
Embodiment 4: circle bud Cillium is prepared with inulin composition with functions capsule
Formula forms:
Circle bud Cillium 680g
Inulin 100g
Magnesium stearate 4g
Preparation method:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin is mixed homogeneously with the magnesium stearate of formula ratio；
3) according to implant weight needed for every capsules by step 2) mixture is filled into capsulae vacuus, makes 2000 capsules.
Embodiment 5: circle bud Cillium is prepared with inulin composition with functions capsule
Formula forms:
Circle bud Cillium 680g
Inulin 100g
Micropowder silica gel 4g
Preparation method:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin is mixed homogeneously with the micropowder silica gel of formula ratio；
3) according to implant weight needed for every capsules by step 2) mixture is filled into capsulae vacuus, makes 2000 capsules.
Embodiment 6: circle bud Cillium is prepared with inulin composition with functions tablet
Formula forms:
Preparation method:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin is mixed homogeneously with the carboxymethyl starch sodium of formula ratio, pregelatinized Starch, magnesium stearate；
3) sheet of 1.0g weight it is pressed into；
4) stomach dissolution type film coating powder is dissolved in ethanol so that it is dispersed；
5) sheet weighed up is put in coating pan, by step 4) in solution be uniformly sprayed on sheet, to obtain final product, to prepare into 1200.
Embodiment 7: circle bud Cillium is prepared with inulin composition with functions tablet
Formula forms:
Preparation method:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin is mixed homogeneously with the microcrystalline Cellulose of formula ratio, polyvinylpolypyrrolidone, magnesium stearate；
3) sheet of 1.0g weight it is pressed into；
4) stomach dissolution type film coating powder is dissolved in ethanol so that it is dispersed；
5) sheet weighed up is put in coating pan, by step 4) in solution be uniformly sprayed on sheet, to obtain final product, to prepare into 1200.
Embodiment 8: circle bud Cillium is prepared with inulin composition with functions tablet
Formula forms:
Preparation method:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin is mixed homogeneously with the low-substituted hydroxypropyl cellulose of formula ratio, pregelatinized Starch, magnesium stearate；
3) sheet of 1.0g weight it is pressed into；
4) stomach dissolution type film coating powder is dissolved in ethanol so that it is dispersed；
5) sheet weighed up is put in coating pan, by step 4) in solution be uniformly sprayed on sheet, to obtain final product, to prepare into 1200.
Experimental example 1 is justified the recipe determination of bud Cillium and inulin composition with functions and improves the effect experiment of constipation
For studying circle bud Cillium and the inulin composition with functions Constipation to enterokinesia inhibition mice, use the animal model compared with normal animal model being similar to mankind's constipation to be preferred, in this research, therefore adopt the diarrhea compound recipe ground temporary Intestinal motility suppressing mice of fragrant promise vinegar.This research is also used pigment flow method, has selected the mice enterokinesia inhibition that can measure intestinal propulsion experiment, with the activated carbon powder of black for indicator, with prepared Chinese ink at the advance distance of intestinal for index.Adopting identical test method and condition, with the folk prescription of each raw material in compositions, compositions of the present invention is carried out effect contrast test, the sample simultaneously also raw material in compositions obtained in different ratio ratio carries out effect contrast test.
1, material and method
1.1 samples:
1), folk prescription sample:
A group: circle bud Cillium 8.0 parts, white sugar 2.0 parts.
B group: inulin 8.0 parts, white sugar 2.0 parts.
2), composition sample:
C group: circle bud Cillium 5.0 parts, inulin 3.0 parts, white sugar 2.0 parts.
D group: circle bud Cillium 6.0 parts, inulin 2.0 parts, white sugar 2.0 parts.
E group: circle bud Cillium 6.8 parts, inulin 1.0 parts, white sugar 2.0 parts.
1.2 laboratory animals and packet:
Selecting 17.0～19.0gICR healthy male mice group 135, secondary animal room is raised.Animal presses body weight random packet, often group 15, and body weight carries out during packet harmonious inspection.Experimental animal is quarantined before the test and is observed 7 days, and in whole process of the test, animal feeding is in secondary animal room, and animal freely ingests and drinks water, laboratory temperature 20～25 DEG C, humidity 40～70%.
1.3 instruments and reagent: operating scissors, ophthalmic tweezers, ruler, syringe, balance, prepared Chinese ink (Radix Acaciae senegalis 100g, add water 800mL, boil to solution transparent, add activated carbon 50g and boil 3 times, add water and be settled to 1000mL, R-1132 (takes 20mg (10), add water to 100mL, be made into the suspension of 5mg/kg BW after grinding) before use.
1.4 groups and dose design:
Test sets 9 groups altogether, i.e. blank group, model control group and 7 sample groups (A group, B group, C group, D group, E group, E low dose group and E high dose group)；Wherein A group, B group, C group, D group, E group dosage be 1.42g/kg BW, be equivalent to 10 times of human body taking dose, and the dosage of E low dose group be 0.71g/kg BW, is equivalent to 5 times of human body taking dose；The dosage of E high dose group is 2.84g/kg BW, is equivalent to 20 times of human body taking dose, and blank group and model group give equal-volume distilled water.
1.5 route of administration and administration volume: gastric infusion, gavage amount is 0.2mL/kg BW.
2. test method
2.1 antagonism diphenoxylates suppress Intestinal pushing Experiment on Function
2.1.1 it is grouped
Take the qualified mice of quarantine, be randomly divided into 9 groups, often group 15, namely blank group, model control group, 7 sample groups.
2.1.2 the foundation of model
After packet, each group starts to gavage corresponding medicine, blank group and model comparison treated animal gavage and gives equal-volume distilled water, every day 1 time, continuous 10 days.Within in process of the test every three days, weigh a body weight.After 10 days, the mice fasting of each group can't help water 16 hours.Model group, 7 sample group gavages give compound diphenoxylate (25mg/kg BW), and blank group is to distilled water.
2.1.3 the method for index determining
After compound diphenoxylate 0.5 hour, each sample fraction does not give the carbon powder suspension containing corresponding given the test agent, by 0.2mL/10g BW gavage.After 25 minutes, put to death mice and open abdomen, take small intestinal clip upper end from pylorus, small intestinal suspention, to the intestinal tube of ileocecus, is vertically in line by lower end, and measuring Length of intestine is " total small intestinal length ", it is " prepared Chinese ink propelling length " from pylorus to ink antiperspirant forward position, calculates ink progradation.The computing formula of ink progradation is as follows:
2.2 antagonistic drug physical property constipation tests
Take the qualified mice of quarantine, be randomly divided into 9 groups, namely blank group, model control group, 7 sample groups, often group 15, after packet, each dosage group starts to gavage corresponding medicine, blank group and model comparison treated animal gavage and gives equal-volume distilled water, every day 1 time, continuous 10 days.Within in process of the test every three days, weigh a body weight.After before last process, fasting can't help water 12 hours, except blank group, other are respectively organized gavage and give diphenoxylate 25mg/kg BW, give after diphenoxylate 1 hour, model group gives carbon powder suspension, and sample group gives the carbon powder suspension containing counter sample, and every mice is all individually fed, observed and recorded every mice defecation time first, 6 hours defecation grain numbers and defecation weight.
2.3 experimental data statistics: adopting statistic software SPSS 11.5 to carry out statistical analysis, data represent with X ± S.
3. experimental result
3.1 impacts on body weight
The table 1 impact on Mouse Weight
| Group (g/kg BW) | Number of animals (only) | Starting weight (g) | Weight (g) eventually |
| Blank group | 15 | 20.54±1.13 | 31.72±1.33 |
| Model control group | 15 | 20.15±0.78 | 31.11±1.38 |
| A group | 15 | 20.32±0.79 | 29.99±1.56 |
| B group | 15 | 20.38±0.65 | 30.45±1.23 |
| C group | 15 | 20.22±0.69 | 31.39±1.03 |
| D group | 15 | 20.26±0.67 | 30.83±1.10 |
| E group | 15 | 20.34±0.82 | 30.83±1.03 |
| E low dose group | 15 | 20.37±1.08 | 30.83±1.40 |
| E high dose group | 15 | 20.36±0.67 | 31.39±1.03 |
Note: compare with model control group, * represents that P < 0.05, * * represents P < 0.01.
By the starting weight of the visible each sample group mice of table 1 result, eventually weight, the difference (P > 0.05) that compares with model group that there are no significant.
3.2 antagonism diphenoxylates suppress Intestinal pushing Experiment on Function
Mice Intestinal pushing effect contrast is tested by table 2
Note: compare with blank group, △ represents that P < 0.05, △ △ represents P < 0.01；Compare * with model group and represent that P < 0.05, * * represents P < 0.01.
Table 2 result shows, after giving compound diphenoxylate, model control group ink progradation is significantly lower than blank group (P < 0.01), and namely mice intestinal suppresses propulsion model to set up.Each sample group ink progradation significantly improves, and Sample A group, B group and E low dose group compare with Constipation Model matched group, and difference has significant (P < 0.05)；And sample C group, D group, E group and E high dose group compare with Constipation Model matched group, difference has pole significant (P < 0.01).Showing that the intestinal inhibitory action that diphenoxylate is caused by compositions of the present invention improves significantly effect, effect is substantially better than each raw material folk prescription experimental group.
3.3 pairs of Drug constipation tests
The table 3 impact on Drug constipation
Note: compare with blank group, △ represents that P < 0.05, △ △ represents P < 0.01；Compare * with model control group and represent that P < 0.05, * * represents P < 0.01.
Table 3 result shows, after giving diphenoxylate, model group mice defecation time first is obviously prolonged, fecal grains significantly reduces, stool weight substantially reduces, compare with blank group, there is significant differences (P < 0.01), represent that Constipated mice is successfully established.After administration, comparing with model group, Sample A group, B group and E low dose group defecation time first substantially shorten, fecal grains showed increased, have significant difference (P < 0.05).And sample C group, D group, E group and E high dose group defecation time first substantially shorten, fecal grains showed increased, there is significant differences (P < 0.01), it was shown that the compositions of the present invention motion action effect to promoting small intestinal will be good than folk prescription.
Compare with model group, sample C group defecation weight substantially increases weight, having significant difference (P < 0.05), sample D group, E group and E high dose group defecation weight substantially increase, and have significant differences (P < 0.01).And other is respectively organized stool quality and is not apparent from increasing, there was no significant difference (P > 0.05).Showing that compositions of the present invention will be good than folk prescription to the effect increasing defecation weight, and C, D, E group is compared, E group mice defecation time first is shorter, and fecal grains is more, better effects if, and E group of formula therefore should be selected as the optimization formula of said composition.
Each result of the test comprehensive above draws: the intestinal inhibitory action that diphenoxylate is caused by compositions of the present invention improves significantly effect, and effect is substantially better than each raw material folk prescription experimental group.And compositions of the present invention can substantially shorten defecation time, promote the motion effect of small intestinal, strengthening feces and discharge quantity, increase defecation weight, effect is substantially better than each raw material folk prescription experimental group.Show that compositions of the present invention can significantly improve constipation.
Experimental example 2 mineral element calcium absorption zoopery
1, material and method
1.1 instruments: the general analysis in Beijing TAS990 atomic absorption spectrophotometer；Shanghai is newly opened up XT-9900A type intelligent microwave and is cleared up instrument.
1.2 reagent: calcium gluconate oral solution with effect, Sanjing Pharmaceutical Co., Ltd., Hayao Group produces.
1.3 animals: SD cleaning grade rat male childhood, body weight 80 scholar 10g.
2, test method
2.1 samples
A group: circle bud Cillium 6.8 parts；
B group: circle bud Cillium 6.8 parts, inulin 1.0 parts.
2.2 animal packets: 40 SD rats are randomly divided into 4 groups, often group 10.(1) blank group: normal saline gavage 1.5ml/kg, one day 1 time；(2) matched group: rat oral gavage gives calcium gluconate oral solution with effect 1.5ml/kg, one day 1 time；(3) test group A: rat oral gavage gives above-mentioned A group sample 1.42g/kg BW and calcium gluconate oral solution with effect 1.5ml/kg, a day 1 time.(3) experiment group B: rat oral gavage gives above-mentioned B group sample 1.42g/kg BW and calcium gluconate oral solution with effect 1.5ml/kg, a day 1 time.Each group all gives identical forage feed without calcium above.
2.3 route of administration: gastric infusion.
2.4 determination of calcium content methods: atomic absorption spectrophotometry.Every day measures above-mentioned each group of rat serum calcium content, METHOD FOR CONTINUOUS DETERMINATION 10 days.
The calculating of 2.5 indexs of correlation: take in calcium (mg)=gavage calcium；The apparent absorptivity %=(taking in calcium-excrement calcium) of calcium/take in calcium × 100%
2.5 data process and statistics
Adopt statistic software SPSS 11.5 carry out statistical analysis, data withRepresent.
The impact of Calcium-ion absorption is tested by 2.6
Calcium-ion absorption is affected experimental data by table 4
Note: * represents that test group compares with matched group, p < 0.05, has significant difference；* represents that test group compares with matched group, p < 0.01, has significant differences.
Result shows, the blood calcium of rat is had significant impact by test A group (circle bud Cillium), when testing the 8th day, rat serum calcium content substantially reduces (p < 0.01) compared with matched group, and instruction sheet quadrat sampling product circle bud Semen Plantaginis shell hinders the absorption of mineral element calcium to a certain extent；And compared with matched group, rat serum calcium content there was no significant difference, and illustrates that inulin can promote that mineral element absorbs to test B group (circle bud Cillium and inulin composition with functions), compensate for the defect of circle bud Cillium folk prescription sample.Above-mentioned conclusion can also be drawn from the apparent absorptivity data of calcium.
Experimental example 3 circle bud Cillium and the screening of inulin composition with functions capsule adjuvant
Content uniformity assay method: take test sample 20, accurately weighed weight, pours out content (must not lose softgel shell) respectively, and capsule softgel shell little brush or other suitable apparatus are wiped only, distinguish accurately weighed softgel shell weight again, obtain the tolerant loading amount of every intragranular and average loading amount.Every loading amount, compared with average loading amount, more than 2, and must not must not have 1 overrun 1 times beyond content uniformity limit.
The screening of table 5 circle bud Cillium and inulin composition with functions capsule adjuvant
From the above experimental results, when Pulvis Talci is as fluidizer, the good fluidity of capsule filling, content uniformity is less, therefore selects embodiment 3 as the preferred formula of this capsule.
Experimental example 4 circle bud Cillium and the screening of inulin composition with functions additive of tablet
Disintegration time mensuration method: adopt lift disintegration tester; take this product and be placed in hanging basket; hang on support by hanging basket by the stainless steel shaft of upper end; immerse in 1000m1 beaker; and regulate hanging basket position and make it drop to during low spot screen cloth from beaker bottom 25mm; fill the hydrochloric acid solution that temperature is 37 DEG C of scholars 1 DEG C in beaker, adjustment height of water level make hanging basket rise to during high point screen cloth is at 15mm place, underwater, hanging basket top can not be immersed in solution.Require that Film coated tablets should whole disintegrates in 30 minutes.
The screening of table 6 circle bud Cillium and inulin composition with functions additive of tablet
Above experimental result shows, tablet physical index and the basic indifference of hardness between each embodiment, and the tablet disintegration times that formula described in embodiment 8 is made is shorter, disintegrate better effects if, therefore selects formula described in embodiment 8 as more preferably formula.
Claims (10)
1. one kind there is loosening bowel to relieve constipation, improve the distribution of human body intestinal canal flora, regulating intestinal canal healthy, the compositions of balance mineral absorption, it is characterized in that, the active component of said composition by justify bud Cillium and inulin form, the weight proportion of the two is: 53～73:5～25.
2. compositions according to claim 1, it is characterised in that the weight proportion of circle bud Cillium and inulin is 68:10.
3. the compositions of the present invention can be any edible dosage form, these dosage forms include: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, suspensoid, powder, preferably, tablet, electuary, capsule.
4. compositions according to claim 1, it is characterised in that described electuary, is grouped into by the one-tenth that following unit is weight portion:
Wherein, described sweeting agent is selected from: one or more in white sugar, saccharin sodium, aspartame, acesulfame potassium, stevioside, xylitol；
Wherein, described edible essence is selected from: Hami melon essence, vanilla, apple essence, Fructus Citri tangerinae essence,
One or more in flavoring pineapple essence, fragrant citrus essence.
5. compositions according to claim 1, it is characterised in that described capsule, is grouped into by the one-tenth that following unit is weight portion:
Circle bud Cillium 53～73 weight portion
Inulin 5～25 weight portion
Lubricant 2～8 weight portion
Wherein, described lubricant is one or more in magnesium stearate, Pulvis Talci, polyethylene glycols, micropowder silica gel.
6. compositions according to claim 1, it is characterised in that described tablet, is grouped into by the one-tenth that following unit is weight portion:
Wherein, described binding agent is one or more in water, ethanol, starch slurry, sodium carboxymethyl cellulose, hypromellose, low-substituted hydroxypropyl cellulose, methylcellulose and ethyl cellulose, cross-linking sodium carboxymethyl cellulose；
Wherein, described disintegrating agent is one or more in dried starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose；
Wherein, described lubricant is one or more in magnesium stearate, Pulvis Talci, polyethylene glycols, differential silica gel.
7. the preparation method of the compositions described in claim 1, it is characterised in that the preparation of electuary, comprises the following steps:
Formula forms:
Preparation method:
1) formula ratio weighs circle bud Cillium, inulin, white sugar, crosses 60 mesh sieves, standby；Arabic gum is weighed by formula ratio, fragrant citrus essence, standby；
2) by load weighted arabic gum, fragrant citrus essence is sufficiently mixed stirring according to equal increments method, obtains adjuvant mixture, standby；
3) by step 1) in circle bud Cillium, inulin, white sugar and step 2) in the adjuvant mixture that obtains be sufficiently mixed, obtain powder mixture, to obtain final product.
8. the preparation method of the compositions described in claim 1, it is characterised in that the preparation of capsule, comprises the following steps:
Formula forms:
Circle bud Cillium 680g
Inulin 100g
Pulvis Talci 4g
Preparation method:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin is mixed homogeneously with the Pulvis Talci of formula ratio；
3) according to implant weight needed for every capsules by step 2) mixture is filled into capsulae vacuus,.
9. the preparation method of the compositions described in claim 1, it is characterised in that the preparation of tablet, comprises the following steps:
Formula forms:
Preparation method:
1) weigh circle bud Cillium, inulin by formula ratio, cross 60 mesh sieves, standby；
2) by the circle bud Cillium after sieving, inulin is mixed homogeneously with the low-substituted hydroxypropyl cellulose of formula ratio, pregelatinized Starch, magnesium stearate；
3) sheet of 1.0g weight it is pressed into；
4) stomach dissolution type film coating powder is dissolved in ethanol so that it is dispersed；
5) sheet weighed up is put in coating pan, by step 4) in solution be uniformly sprayed on sheet, to obtain final product.
10. the compositions described in claim 1 preparing loosening bowel to relieve constipation, improve human body intestinal canal health, application in the medicine of balance mineral absorption or field of food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610200045.2A CN105796662A (en) | 2016-03-31 | 2016-03-31 | Psyllium seed husk powder and inulin composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610200045.2A CN105796662A (en) | 2016-03-31 | 2016-03-31 | Psyllium seed husk powder and inulin composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105796662A true CN105796662A (en) | 2016-07-27 |
Family
ID=56460008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610200045.2A Pending CN105796662A (en) | 2016-03-31 | 2016-03-31 | Psyllium seed husk powder and inulin composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105796662A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106465946A (en) * | 2016-09-19 | 2017-03-01 | 江苏慧博生物科技有限公司 | A kind of loosening bowel to relieve constipation dietary fiber |
| CN106605923A (en) * | 2016-10-12 | 2017-05-03 | 西安源森生物科技有限公司 | Compound dietary fiber and preparation method thereof |
| CN106822253A (en) * | 2017-03-24 | 2017-06-13 | 天津商业大学 | Application of the circle bud isapgol husk dietary fiber in intestinal tract injury protection preparation is prepared |
| CN107396949A (en) * | 2017-07-18 | 2017-11-28 | 惠州同富康生物科技有限公司 | A kind of detoxicating intestine beautifying face and moistering lotion biscuit and preparation method thereof |
| CN108271983A (en) * | 2017-01-05 | 2018-07-13 | 乐康珍泰（天津）生物技术有限公司 | Solid beverage for regulating intestines and relaxing bowels and preparation method thereof |
| CN109170906A (en) * | 2018-10-15 | 2019-01-11 | 上海拜伦斯维生物科技中心 | The formula of prebiotics generation meal milk shake (prebiotic meal) |
| CN109497385A (en) * | 2018-12-14 | 2019-03-22 | 大连双迪科技股份有限公司 | Oil cuts enzyme composition |
| CN110973604A (en) * | 2019-11-22 | 2020-04-10 | 坤承(北京)健康管理有限公司 | Cereal meal replacement powder for diabetics to eat |
| CN111134329A (en) * | 2018-11-06 | 2020-05-12 | 深圳华大生命科学研究院 | Application of plant polysaccharide in preparation of intestinal type-related hyperuricemia drug |
| CN111616336A (en) * | 2020-05-28 | 2020-09-04 | 江门市澳新食品有限公司 | Pastry stuffing and pastry capable of promoting intestinal peristalsis and benefiting intestinal health and preparation method of pastry stuffing and pastry |
| CN112617204A (en) * | 2020-12-15 | 2021-04-09 | 山东欣瑞文生物科技有限公司 | Arabic gum composition with bowel relaxing and constipation relieving effects |
| WO2021192663A1 (en) * | 2020-03-25 | 2021-09-30 | 日清食品ホールディングス株式会社 | Psyllium seed coat granules and production method for same, and powdered drink containing psyllium seed coat granules |
| CN115119936A (en) * | 2021-03-29 | 2022-09-30 | 袁亚娟 | Pill for burning fat, losing weight and expelling toxin and preparation method thereof |
| CN115944087A (en) * | 2023-01-16 | 2023-04-11 | 深圳市君恒生物科技有限公司 | Probiotic composition for relieving alcoholism and protecting liver, product and application thereof |
| JP7516281B2 (en) | 2020-03-25 | 2024-07-16 | 日清食品ホールディングス株式会社 | Psyllium husk granules, manufacturing method thereof, and powdered beverage containing psyllium husk granules |
-
2016
- 2016-03-31 CN CN201610200045.2A patent/CN105796662A/en active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106465946A (en) * | 2016-09-19 | 2017-03-01 | 江苏慧博生物科技有限公司 | A kind of loosening bowel to relieve constipation dietary fiber |
| CN106605923A (en) * | 2016-10-12 | 2017-05-03 | 西安源森生物科技有限公司 | Compound dietary fiber and preparation method thereof |
| CN108271983A (en) * | 2017-01-05 | 2018-07-13 | 乐康珍泰（天津）生物技术有限公司 | Solid beverage for regulating intestines and relaxing bowels and preparation method thereof |
| CN106822253A (en) * | 2017-03-24 | 2017-06-13 | 天津商业大学 | Application of the circle bud isapgol husk dietary fiber in intestinal tract injury protection preparation is prepared |
| CN107396949A (en) * | 2017-07-18 | 2017-11-28 | 惠州同富康生物科技有限公司 | A kind of detoxicating intestine beautifying face and moistering lotion biscuit and preparation method thereof |
| CN107396949B (en) * | 2017-07-18 | 2018-05-29 | 惠州同富康生物科技有限公司 | A kind of detoxicating intestine beautifying face and moistering lotion biscuit and preparation method thereof |
| CN109170906A (en) * | 2018-10-15 | 2019-01-11 | 上海拜伦斯维生物科技中心 | The formula of prebiotics generation meal milk shake (prebiotic meal) |
| CN111134329A (en) * | 2018-11-06 | 2020-05-12 | 深圳华大生命科学研究院 | Application of plant polysaccharide in preparation of intestinal type-related hyperuricemia drug |
| CN109497385A (en) * | 2018-12-14 | 2019-03-22 | 大连双迪科技股份有限公司 | Oil cuts enzyme composition |
| CN110973604A (en) * | 2019-11-22 | 2020-04-10 | 坤承(北京)健康管理有限公司 | Cereal meal replacement powder for diabetics to eat |
| WO2021192663A1 (en) * | 2020-03-25 | 2021-09-30 | 日清食品ホールディングス株式会社 | Psyllium seed coat granules and production method for same, and powdered drink containing psyllium seed coat granules |
| JP7516281B2 (en) | 2020-03-25 | 2024-07-16 | 日清食品ホールディングス株式会社 | Psyllium husk granules, manufacturing method thereof, and powdered beverage containing psyllium husk granules |
| CN111616336A (en) * | 2020-05-28 | 2020-09-04 | 江门市澳新食品有限公司 | Pastry stuffing and pastry capable of promoting intestinal peristalsis and benefiting intestinal health and preparation method of pastry stuffing and pastry |
| CN112617204A (en) * | 2020-12-15 | 2021-04-09 | 山东欣瑞文生物科技有限公司 | Arabic gum composition with bowel relaxing and constipation relieving effects |
| CN115119936A (en) * | 2021-03-29 | 2022-09-30 | 袁亚娟 | Pill for burning fat, losing weight and expelling toxin and preparation method thereof |
| CN115944087A (en) * | 2023-01-16 | 2023-04-11 | 深圳市君恒生物科技有限公司 | Probiotic composition for relieving alcoholism and protecting liver, product and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105796662A (en) | Psyllium seed husk powder and inulin composition | |
| TWI663981B (en) | Powder having function on regulating gastrointestinal tract and protecting gastric mucosa and the preparation method and application thereof | |
| Madgulkar et al. | Characterization of psyllium (Plantago ovata) polysaccharide and its uses | |
| KR100937455B1 (en) | Bowel movement promotion functional food containing psyllium seed, rice bran fermentation extracts and yeast extracts and manufacturing method thereof | |
| CN105211687A (en) | A kind of composition and method of making the same and purposes | |
| CN107518418A (en) | Application of the dietary fiber as metabolism regulators | |
| Kochhar et al. | Effect of supplementation of traditional medicinal plants on blood glucose in non–insulin-dependent diabetics: A pilot study | |
| CN101103811A (en) | Health food capable of relaxing the bowels | |
| CN106666312A (en) | Health-care food for assisting blood glucose decreasing and preparation method of granule and capsule thereof | |
| CN1980682A (en) | Flaxseeds for body weight management | |
| CN110447902B (en) | Composition with weight-losing effect | |
| CN105079309B (en) | Composition for relaxing bowel | |
| CN106729092A (en) | A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application | |
| CN104705658A (en) | Health food with bone density improving function | |
| CN104489462A (en) | Xylooligosaccharide probiotic powder | |
| CN106465946A (en) | A kind of loosening bowel to relieve constipation dietary fiber | |
| CN105997979A (en) | Medicine composition, medicine containing medicine composition for regulating uric acid content in blood and application thereof | |
| CN111228238B (en) | Pharmaceutical composition containing orlistat and oligosaccharide | |
| CN112931883A (en) | Prebiotic composition and preparation method and application thereof | |
| JP7091344B2 (en) | Prebiotic dietary supplements to promote amylose-degrading activity and activity of short-chain fatty acid-producing microorganisms | |
| CN104415214B (en) | Purposes of the black garlic extract in microbial population of animal intestinal tract is adjusted | |
| Bortolotti et al. | Effect of a balanced mixture of dietary fibers on gastric emptying, intestinal transit and body weight | |
| CN109999088A (en) | A kind of compound preparation and its application with effect of relaxing bowel | |
| CN102028138B (en) | Composition for catharsis and preparation method thereof | |
| CN105995980B (en) | A kind of composition and preparation method thereof with Weight management effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160727 |
|
| RJ01 | Rejection of invention patent application after publication |